title: Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity.
abstract: This article represents the proceedings of a symposium at the 2003 annual meeting RSA in Fort Lauderdale, FL. It was organized and cochaired by Charlene E. Le Fauve and Carrie L. Randall. The presentations were (1) Introduction, by Charlene E. Le Fauve and Raye Z. Litten; (2) Treatment of co-occurring alcohol use and anxiety disorders, by Carrie L. Randall and Sarah W. Book; (3) Pharmacological treatment of alcohol dependent patients with comorbid depression, by Darlene H. Moak; (4) Efficacy of valproate in bipolar alcoholics: a double blind, placebo-controlled study, by Ihsan M. Salloum, Jack R. Cornelius, Dennis C. Daley, Levent Kirisci, Johnathan Himmelhoch, and Michael E. Thase; (5) Alcoholism and schizophrenia: effects of antipsychotics, by Alan I. Green, Robert E. Drake, Suzannah V. Zimmet, Rael D. Strous, Melinda Salomon, and Mark Brenner; and (6) Conclusions, by Charlene E. Le Fauve; discussant, Raye Z. Litten. Alcohol-dependent individuals have exceptionally high rates of co-occurring psychiatric disorders. Although this population is more likely to seek alcoholism treatment than noncomorbid alcoholics, the prognosis for treatment is often poor, particularly among patients with more severe psychiatric illnesses. Development of effective interventions to treat this population is in the early stages of research. Although the interaction between the psychiatric condition and alcoholism is complex, progress has been made. The NIAAA has supported a number of state-of-the-art pharmacological and behavioral trials in a variety of comorbid psychiatric disorders. Some of these trials have been completed and are presented here. The symposium presented some new research findings from clinical studies with the aim of facilitating the development of treatments that improve alcohol and psychiatric outcomes among individuals with alcohol-use disorders and co-occurring psychiatric disorders. The panel focused on social anxiety disorder, depression, bipolar disorder, and schizophrenia.
authors.affiliation: Division of Clinical and Prevention Research, Treatment Research Branch, NIAAA, Bethesda, Maryland, USA. clefauve@NIAAA.nih.gov
authors.forename: Charlene E
authors.initials: CE
authors.lastname: Le Fauve
authors.forename: Raye Z
authors.initials: RZ
authors.lastname: Litten
authors.forename: Carrie L
authors.initials: CL
authors.lastname: Randall
authors.forename: Darlene H
authors.initials: DH
authors.lastname: Moak
authors.forename: Ihsan M
authors.initials: IM
authors.lastname: Salloum
authors.forename: Alan I
authors.initials: AI
authors.lastname: Green
mesh_terms: D000437:Alcoholism / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology*; D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use; D015897:Comorbidity; D017831:Diagnosis, Dual (Psychiatry) / Q000379:methods; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology*; D012955:Societies, Medical; D014481:United States; D014635:Valproic Acid / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D014635:Valproic Acid